Two biotech reverse mergers were announced within hours of each other, as companies explore alternative public-market routes while the IPO window shows signs of thawing in 2026. Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal paired with a $225 million private placement, extending Lisata’s portfolio into cardioendocrine development led by MAR001/005 in Phase 2b. On the same day, Aethlon Medical announced an all-stock merger with North Immunology alongside a $180 million private placement. The combined company, trading under ticker NRTX, plans to advance NOR-101, a half-life-extended IL-13 × IL-18 bispecific antibody for atopic dermatitis. Together, the transactions reflect how late-stage pipeline assets and financing needs are shaping public-market strategy for small and mid-cap biotechs.